Uncategorized Archives - Page 15 of 134

FridayFeb 23, 2024 10:30 am

Sigyn Therapeutics Inc. (SIGYD) CEO Discusses Opportunities to Treat Cancer and Drug-Resistant Pathogens in Letter to Shareholders

Sigyn Therapeutics Chairman and CEO James A. Joyce recently provided a letter to shareholders that discussed the company’s therapeutic opportunities, challenges, and decision-making processes The letter overviewed the company’s candidate technologies to enhance the performance of cancer therapies (ImmunePrep(TM), ChemoPrep(TM), and ChemoPure(TM)), and provided an update on Sigyn Therapy(TM), an extracorporeal drug purification technology to address pathogen-associated conditions that are beyond the reach of drugs James A. Joyce, the Chairman and CEO of development-stage medical technology company Sigyn Therapeutics (OTCQB: SIGYD, SIGY), recently discussed the company’s opportunities, challenges, and decision-making processes in a letter to shareholders (https://ibn.fm/wGTqS). The company is currently…

WednesdayFeb 21, 2024 12:45 pm

Astiva Health Navigating the Future of Healthcare with a Vision for Culturally Responsive Medicare Advantage

Astiva Health’s culturally inclusive approach sets a new precedent in the Medicare Advantage market Enrollment in Medicare Advantage programs is projected to encompass half of all Medicare enrollments by 2024, with Astiva Health leading the charge in service expansion and inclusivity Astiva Health is committed to reshaping healthcare delivery with increased access to quality healthcare for diverse populations In a landscape where more individuals are becoming eligible for Medicare, Astiva Health is carving out a niche as a rapidly growing Medicare Advantage Prescription Drug (“MAPD”) health plan. Astiva stands out by redefining personalized and comprehensive healthcare standards. Reflecting its success, Astiva recently…

WednesdayFeb 21, 2024 12:00 pm

Sigyn Therapeutics Inc. (SIGYD) Advancing Novel Therapeutic Technologies to Enhance the Benefit of Cancer Therapies, Treat Pathogen-Associated Conditions Beyond the Reach of Drugs

Sigyn Therapeutics has designed a pipeline of medical technologies to improve cancer treatment outcomes by reducing the circulating presence of bloodstream particles that decoy or block the intended delivery of cancer therapies. At present, less than 2% of therapeutic antibodies and chemotherapy doses administered to cancer patients are delivered to tumor cell targets The company has also created a medical technology to reduce the circulating presence of off-target chemotherapy from the bloodstream to reduce patient toxicity and organ damage The company’s lead therapeutic candidate addresses life-threatening conditions that are pathogen-induced and not addressed with drug therapies Sigyn Therapeutics (OTCQB: SIGYD,…

TuesdayFeb 20, 2024 9:45 am

PaxMedica Inc. (NASDAQ: PXMD) Developing Pipeline of Products to Address Prevalence and Unmet Medical Needs of Autism Spectrum Disorder

The CDC estimates that the prevalence of ASD in the United States is 1 in 36 children, with no approved pharmacologic treatments targeting the cause and symptoms PaxMedica is developing novel anti-purinergic therapies for the treatment of ASD and other serious conditions with intractable neurologic symptoms, and is on a promising path to address the unmet medical needs and bring hope to millions Company CEO Howard Weisman recently shared insights into PaxMedica’s achievements and advancements in a Fireside Chat video, underscoring the company’s commitment to groundbreaking therapies and transformative solutions The prevalence of autism spectrum disorder (“ASD”) in the United…

TuesdayFeb 13, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Revolutionizes Approach to Restore Neuronal Health in Neurodegenerative Disease with CNM-Au8(R)

Neurodegenerative diseases pose a significant challenge in healthcare, yet treatment options remain limited CNM-Au8(R) has demonstrated remarkable efficacy across various nervous system cell types, with its ability to target fundamental deficiencies associated with dying neurons Gold nanocrystals found in CNM-Au8 act as miniature mitochondria, providing neurons with much-needed ATP energy while simultaneously converting toxic reactive oxygen species into harmless compounds Neurodegenerative diseases pose a significant challenge in healthcare, yet treatment options remain limited. Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, is working on a potentially groundbreaking…

WednesdayFeb 07, 2024 9:00 am

Longeveron Inc.’s (NASDAQ: LGVN) Long-Term Follow-Up Data from Its ELPIS I Clinical Trial Presented at the 2023 Annual Scientific Sessions of the American Heart Association

A poster about Longeveron’s long-term follow-up data from its ELPIS I clinical trial was presented at the 2023 Scientific Sessions of the American Heart Association in November 2023 The poster showed that 100% of the 10 patients enrolled in the study survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-B(TM) during their Stage II surgery The data supports Longeveron’s ongoing ELPIS II study, which has exceeded its 50% enrollment threshold The company believes the long-term follow-up data underscore the potential for Lomecel-B(TM) as a much-needed therapeutic innovation for HLHS patients Historical results from outside…

TuesdayFeb 06, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Reports ‘Unprecedented,’ Statistically Significant Long-Term Clinical Improvements for VISIONARY-MS Trial Participants with Stable Relapsing-Remitting MS

Clene recently reported new results from the open-label, long-term extension (“LTE”) of the VISIONARY-MS trial, involving participants with stable relapsing Multiple Sclerosis (“MS”) through week 144 (over 2.75 years) after the initial randomization Results from the 48-week double-blind period showed statistically significant improvements in vision (primary endpoint), as well as a combined improvement in cognition, walking speed, upper extremity function, and vision (secondary endpoint) with CNM-Au8 treatment, with further significant improvements in both vision and cognition extending throughout the 96-week LTE One of the trial’s key clinical advisors hailed the results as robust and consistent, describing the observed long-term clinical…

MondayFeb 05, 2024 12:00 pm

Astiva Health Differentiating Itself in Medicare Market, Working to Provide ‘Robust, Stable’ Offerings

CMS forecasts enrollment in Medicare Advantage programs will increase from 31.6 million in 2023 to 33.8 million in 2024 Astiva Health recently expanded into three Southern California counties, resulting in the company reaching the 10,000-member milestone mark Astiva is committed to reshape healthcare delivery, increased access to quality healthcare In a space where a growing number of individuals are qualifying for Medicare, Astiva Health is differentiating itself as a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan focused on redefining the standards of personalized and comprehensive healthcare. As an indication of its success in, Astiva company recently reached a key milestone, surpassing the…

MondayFeb 05, 2024 9:00 am

Astrotech Corp. (NASDAQ: ASTC) Positioning TRACER 1000(TM) as Next-Generation Solution for the Explosive Trace Detector Market

1st Detect, a wholly owned subsidiary of mass spectrometry company Astrotech, is offering its breakthrough TRACER 1000(TM) Explosive Trace Detector (“ETD”) in markets that accept ECAC certification The TRACER 1000(TM) ETD is designed to outperform ETDs currently used at airports, cargo and other secured facilities, as well as at borders Astrotech is working to position its product as the next-generation solution for the ETD market at a time when many of the existing IMS-based ETDs are due for replacement Keenly watching the developments in the field of explosives and narcotics detection at airports is Astrotech (NASDAQ: ASTC), a mass spectrometry…

ThursdayFeb 01, 2024 9:00 am

Astiva Health CEO Dr. Tri Nguyen Discusses Company’s Growth and Vision on The Bell2Bell Podcast

In a recent episode of the 'Bell2Bell Podcast' hosted by Stuart Smith, Astiva Health was spotlighted as a significant player in the Medicare Advantage Prescription Drug (“MAPD”) sector. The episode featured an exclusive interview with Astiva Health’s Co-Founder and CEO, Dr. Tri Nguyen, a renowned expert in internal medicine and cardiology. Listen to the full interview to hear Dr. Nguyen discuss Astiva Health’s journey since its inception in 2020 and its expansion plans. He shared insightful details about the company's expansion to Los Angeles, San Bernardino, and Riverside from January 1, 2024, marking a pivotal phase in transforming healthcare delivery.…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Sigyn Therapeutics Inc. (SIGYD) CEO Discusses Opportunities to Treat Cancer and Drug-Resistant Pathogens in Letter to Shareholders

Astiva Health Navigating the Future of Healthcare with a Vision for Culturally Responsive Medicare Advantage

Sigyn Therapeutics Inc. (SIGYD) Advancing Novel Therapeutic Technologies to Enhance the Benefit of Cancer Therapies, Treat Pathogen-Associated Conditions Beyond the Reach of Drugs

PaxMedica Inc. (NASDAQ: PXMD) Developing Pipeline of Products to Address Prevalence and Unmet Medical Needs of Autism Spectrum Disorder

Clene Inc. (NASDAQ: CLNN) Revolutionizes Approach to Restore Neuronal Health in Neurodegenerative Disease with CNM-Au8(R)

Longeveron Inc.’s (NASDAQ: LGVN) Long-Term Follow-Up Data from Its ELPIS I Clinical Trial Presented at the 2023 Annual Scientific Sessions of the American Heart Association

Clene Inc. (NASDAQ: CLNN) Reports ‘Unprecedented,’ Statistically Significant Long-Term Clinical Improvements for VISIONARY-MS Trial Participants with Stable Relapsing-Remitting MS

Astiva Health Differentiating Itself in Medicare Market, Working to Provide ‘Robust, Stable’ Offerings

Astrotech Corp. (NASDAQ: ASTC) Positioning TRACER 1000(TM) as Next-Generation Solution for the Explosive Trace Detector Market

Astiva Health CEO Dr. Tri Nguyen Discusses Company’s Growth and Vision on The Bell2Bell Podcast

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search